

RECEIVED

MAR 18 2003

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants:** B. Tjellstrom, et al. **Examiner:** J. H. Roark  
**Serial No.:** 09/925,671 **Art Unit:** 1644  
**Filing Date:** August 9, 2001 **Docket:** 111332  
**For:** ORAL IMMUNOGLOBULIN **Date:** March 11, 2003  
TREATMENT FOR INFLAMMATORY  
BOWEL DISEASE

Commissioner for Patents  
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following disclosures, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. U.S. Patent No. 5,869,048, dated 4/10/96;
2. U.S. Patent No. 5,853,697, dated 10/25/95; and
3. U.S. Patent No. 5,833,984, dated 2/18/94.

---

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on March 11, 2003.

Dated: March 11, 2003


  
Michelle Mustafa

Pursuant to 37 C.F.R. §1.98(d), copies of publications are not provided, as these references were previously cited by the Examiner in the parent case, Serial Number 09/247,396, filed on February 10, 1999.

Consideration of this Information Disclosure Statement is respectfully requested, since the art provided may be material to the examination of the present application as defined under 37 C.F.R. §1.56.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,

  
Peter I. Bernstein  
Reg. No. 43,497

Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343  
PIB/XZ:ab

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

**Under 37 CFR 1.97(b) or 1.97(c)**

Docket No.  
11133z

In Re Application Of: **B. Tjellstrom, et al.**

Serial No.  
09/925,671

Filing Date  
August 9, 2001

Examiner  
J. H. Roark

Group Art Unit  
1644

Title: **ORAL IMMUNOGLOBULIN TREATMENT FOR INFLAMMATORY BOWEL DISEASE**

Address to:

**Assistant Commissioner for Patents  
Washington, D.C. 20231**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).

# TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Under 37 CFR 1.97(b) or 1.97(c)

Docket No.  
11133z

In Re Application: B. Tjellstrom, et al.

Serial No.

09/925,671

Filing Date

August 9, 2001

Examiner

J. H. Roark

Group Art Unit

1644

ORAL IMMUNOGLOBULIN TREATMENT FOR INFLAMMATORY BOWEL DISEASE

## Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **19-3886/RCT** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

### Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

### Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited **March 11, 2003** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

\_\_\_\_\_  
Signature of Person Mailing Correspondence

Michelle Mustafa

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

*Peter I. Bernstein*  
Signature

Dated: March 11, 2003

Peter I. Bernstein  
Registration No. 43,497  
Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

cc: PIB/XZ:ab